Mutations in MYH7 reduce the force generating capacity of sarcomeres in human familial hypertrophic cardiomyopathy
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
AIMS: Familial hypertrophic cardiomyopathy (HCM), frequently caused by sarcomeric gene mutations, is characterized by cellular dysfunction and asymmetric left-ventricular (LV) hypertrophy. We studied whether cellular dysfunction is due to an intrinsic sarcomere defect or cardiomyocyte remodelling. METHODS AND RESULTS: Cardiac samples from 43 sarcomere mutation-positive patients (HCMmut: mutations in thick (MYBPC3, MYH7) and thin (TPM1, TNNI3, TNNT2) myofilament genes) were compared with 14 sarcomere mutation-negative patients (HCMsmn), eight patients with secondary LV hypertrophy due to aortic stenosis (LVHao) and 13 donors. Force measurements in single membrane-permeabilized cardiomyocytes revealed significantly lower maximal force generating capacity (Fmax) in HCMmut (21 ± 1 kN/m²) and HCMsmn (26 ± 3 kN/m²) compared with donor (36 ± 2 kN/m²). Cardiomyocyte remodelling was more severe in HCMmut compared with HCMsmn based on significantly lower myofibril density (49 ± 2 vs. 63 ± 5%) and significantly higher cardiomyocyte area (915 ± 15 vs. 612 ± 11 μm²). Low Fmax in MYBPC3mut, TNNI3mut, HCMsmn, and LVHao was normalized to donor values after correction for myofibril density. However, Fmax was significantly lower in MYH7mut, TPM1mut, and TNNT2mut even after correction for myofibril density. In accordance, measurements in single myofibrils showed very low Fmax in MYH7mut, TPM1mut, and TNNT2mut compared with donor (respectively, 73 ± 3, 70 ± 7, 83 ± 6, and 113 ± 5 kN/m²). In addition, force was lower in MYH7mut cardiomyocytes compared with MYBPC3mut, HCMsmn, and donor at submaximal [Ca²⁺]. CONCLUSION: Low cardiomyocyte Fmax in HCM patients is largely explained by hypertrophy and reduced myofibril density. MYH7 mutations reduce force generating capacity of sarcomeres at maximal and submaximal [Ca²⁺]. These hypocontractile sarcomeres may represent the primary abnormality in patients with MYH7 mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wall stress and patterns of hypertrophy in the human left ventricle.
Grossman, W., Jones, D., & McLaurin, L. P. (1975) · Journal of Clinical Investigation · doi:10.1172/jci108079 · Cited by 2,403 · cited 1×
“Since asymmetric hypertrophy in HCM reflects a concentric type of cardiac remodelling, one would expect that the myofilament proteins are added in series leading to thickening of the ventricular wall.(25)”
BackgroundCUDA, G., FANANAPAZIR, L., EPSTEIN, N. D., & SELLERS, J. R. (1997) · Journal of Muscle Research & Cell Motility · doi:10.1023/a:1018613907574 · Cited by 137
van Dijk, S. J., Paalberends, E. R., Najafi, A., Michels, M., Sadayappan, S., Carrier, L., Boontje, N. M., Kuster, D. W. D., van Slegtenhorst, M., Dooijes, D., et al. (2012) · Circulation: Heart Failure · doi:10.1161/circheartfailure.111.963702 · Cited by 124 · cited 1×
“This decrease is in line with previous results in human myocardium harbouring thick myofilament mutations.(17,22,24,28) The present study shows that an increase in cardiomyocyte hypertrophy and reduction in myofibril density represent major causes of the decrease in cardiomyocyte maximal force in HCM patients.”
ResultSelf-citationThe aging myocardium: roles of mitochondrial damage and lysosomal degradation
Terman, A., & Brunk, U. T. (2005) · Heart, Lung and Circulation · doi:10.1016/j.hlc.2004.12.023 · Cited by 80
Cited by
Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy
Marian, A. J., & Braunwald, E. (2017) · Circulation Research · doi:10.1161/circresaha.117.311059 · Cited by 1,403
“For example, mutations in MYH7 and MYBPC3 negatively affect force generation but those in MYH7 reduce myofibrillar ATPase activity more than those in MYBPC3.(106,107) Accordingly, the energy cost of tension generation is significantly higher for MYH7 than MYBPC3 mutations.”
BackgroundSpudich, J. A. (2014) · Biophysical Journal · doi:10.1016/j.bpj.2014.02.011 · Cited by 269
Hypertrophic obstructive cardiomyopathy
Veselka, J., Anavekar, N. S., & Charron, P. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31321-6 · Cited by 257
Molecular Genetic Basis of Hypertrophic Cardiomyopathy
Marian, A. J. (2021) · Circulation Research · doi:10.1161/circresaha.121.318346 · Cited by 250
Birket, M. J., Ribeiro, M. C., Kosmidis, G., Ward, D., Leitoguinho, A. R., van de Pol, V., Dambrot, C., Devalla, H. D., Davis, R. P., Mastroberardino, P. G., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.025 · Cited by 194
Metadata
- Authors
- Witjas-Paalberends, E. R., Piroddi, N., Stam, K., van Dijk, S. J., Oliviera, V. S., Ferrara, C., Scellini, B., Hazebroek, M., ten Cate, F. J., van Slegtenhorst, M., dos Remedios, C., Niessen, H. W. M., Tesi, C., Stienen, G. J. M., Heymans, S., Michels, M., Poggesi, C., & van der Velden, J.
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-05-13
- Volume
- 99
- Issue
- 3
- Pages
- 432-441
- ISSN
- 0008-6363 (ISSN-L)
- 1755-3245
- OpenAlex
- W1982580326
- Cited by
- 103
- References
- 4
- FWCI
- 5.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.